Transaction DateRecipientSharesTypePriceValue
1st July 2020David Francis Carroll7,500Exercise of derivative$0.00
19th June 2020Venture Capital Iv, L.P. Versant3,428,221Other acquisition or disposition$0.00
19th June 2020Venture Capital Iv, L.P. Versant34,282Other acquisition or disposition$0.00
19th June 2020Venture Capital Iv, L.P. Versant34,282Other acquisition or disposition$0.00
19th June 2020Venture Capital Iv, L.P. Versant21,597Other acquisition or disposition$0.00
4th June 2020Glenn Sblendorio5,855Grant/award etc.$0.00
28th May 2020Glenn Sblendorio1,595Grant/award etc.$0.00
1st April 2020Glenn Sblendorio18,750Exercise of derivative$0.00
6th January 2020David R Guyer3,367Open or private sale$8.07$27,171.69
6th January 2020Keith Westby293Open or private sale$8.07$2,364.51
Iveric Bio
Iveric Bio logo

The company is developing novel therapeutics to treat diseases of the eye. The company is based in San Francisco and has offices in New York and London.


Ticker: OPHT
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1410939
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $108 M (0%)
Assets, Current: $115 M (-10%)
Property, Plant and Equipment, Net: $135 Th (-21%)
Other Assets, Noncurrent: $12 Th (0%)
Assets: $116 M (-11%)
Liabilities, Current: $11 M (-15%)
Liabilities: $11 M (-14%)
Common Stock, Value, Issued: $50 Th (0%)
Common Stock, Shares, Issued: $50 M (0%)
Retained Earnings (Accumulated Deficit): $496 M (3%)
Stockholders' Equity (Parent): $105 M (0%)
Liabilities and Equity: $116 M (-11%)
Research and Development: $14 M (78%)
General and Administrative Expenses: $5 M (-8%)
Operating Income/Loss: $19 M (42%)
Provision for income taxes: $3 M (0%)